GEN ID, S2 Biosciences to develop bird flu treatments

By Elaine Rigoli

Tampa, Fla., May 8 - GEN ID Lab Services, Inc. and S2 Bioscience, Inc. said Monday that they will be developing new drug candidates to treat bird flu infections in humans.

These research efforts seek to develop another class of compounds to counteract the resistance that H5N1 is acquiring through mutations, according to a news release.

Current treatment of H5N1 avian influenza infection includes the use of antiviral therapy such as ribavirin and amantadine and neuraminidase inhibitors such as oseltamivir and zanamivir, the news release said.

GEN ID is a medical testing company located in Fontana, Calif.

S2 Biosciences is a Montreal-based company providing preclinical contract research services to the pharmaceutical industry.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.